Acquisition by Brady Stephen R of 250000 shares of Tempest Therapeutics at 4.66 subject to Rule 16b-3
| TPST Stock | USD 7.46 0.03 0.40% |
Slightly above 62% of Tempest Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Tempest Therapeutics stock suggests that many investors are alarmed at this time. Tempest Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Tempest Therapeutics' earnings reports, geopolitical events, and overall market trends.
Filed transaction by Tempest Therapeutics Director, Officer President And Ceo. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Tempest Therapeutics Fundamental Analysis
We analyze Tempest Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tempest Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tempest Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Tempest Therapeutics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Tempest Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tempest Therapeutics stock to make a market-neutral strategy. Peer analysis of Tempest Therapeutics could also be used in its relative valuation, which is a method of valuing Tempest Therapeutics by comparing valuation metrics with similar companies.
Peers
Tempest Therapeutics Related Equities
| ERAS | Erasca | 5.71 | ||||
| RNXT | RenovoRx | 2.48 | ||||
| FBRX | Forte Biosciences | 0.61 | ||||
| MDIA | Mediaco Holding | 0.79 | ||||
| RNAZ | Transcode Therapeutics | 0.87 | ||||
| INDP | Indaptus Therapeutics | 2.74 |
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.